ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Dual-Stage Microneedle Patch With Lipid Droplet-Mediated 'Capture-Kill' and Sustained Release for Enhanced Wound Healing.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Chronic wound infections, particularly those complicated by antibiotic-resistant bacteria and biofilm formation, present persistent clinical challenges due to limited drug penetration and unresolved inflammation. Here, we report a lipid-droplet-engineered, gallium-loaded sonodynamic therapeutic platform (LDTG) incorporated into a bilayer microneedle (MN) patch co-delivering all-trans retinoic acid (ATRA), termed LDTG A-MNs, for synergistic antibacterial therapy and accelerated wound repair. The engineered LDTG exhibit strong bacteria-targeting capability by mimicking host lipid droplets and efficiently generate reactive oxygen species (ROS) under ultrasound irradiation to achieve potent sonodynamic bactericidal activity. The bilayer MN design enables rapid release of LDTG for targeted bacterial capture, followed by sustained ATRA release to modulate macrophage polarization and promote tissue regeneration. In vitro, LDTG A-MNs demonstrate robust antibacterial and biofilm-disrupting effects, excellent biocompatibility, and enhanced M2-type macrophage polarization. In vivo, LDTG A-MNs combined with ultrasound effectively eradicate bacterial infection, suppress excessive inflammation, improve collagen deposition, enhance angiogenesis, and significantly accelerate wound closure in infected murine skin wounds. This work presents a minimally invasive and infection-responsive MN system that integrates pathogen targeting, sonodynamic antibacterial therapy, and immune-regulated tissue repair, offering a promising therapeutic strategy for the management of complex and refractory infected wounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.